Abcam and Transinsight Collaborate in the Area of Semantic Search Technologies

TransinsightAbcam, a bioscience company specialising in the supply of antibodies from a web-based catalogue and Transinsight, a specialist in semantic search technologies announced a collaboration in the field of protein information quality control using bioinformatics workflows.

Accurately compiling all the required information around antibody targets is a challenging task, which has created the requirement for an automated intelligent computer-based solution to ensure top-quality information content about proteins. For example, an average human gene name has 6 or 7 synonyms and many more spelling variants. Hand-curated databases do not cover all possible ways of naming and spelling genes and hand-curation is a tedious, error prone and labour-intensive task.

"Until recently there were only limited software tools and scientific workflows available to help us automatically produce high quality data sets surrounding each of Abcam’s thousands of antibody targets. We need these data sets to help our customers find the right products", says Dr. Harter, Senior Business Development Manager at Abcam. Harter continues "We were looking for solutions for supporting our team of experts and were impressed by the advanced technologies of Transinsight. The fact that the company operates the semantic search engine GoPubMed.org and has extensive bioinformatics and protein databases expertise made the decision to work with Transinsight easy."

The award winning technology behind GoPubMed fully automates very difficult analyses normally done by scientists with equal or better performance, predicting the necessary information by sophisticated algorithms. "It is good to see how we can significantly enhance our customers' performance by improving their data quality and thus freeing their staff from an unnecessary burden" says Michael R. Alvers, CEO at Transinsight.

Related news articles:

About Abcam
Abcam plc is a producer and distributor of research-grade antibodies and associated products headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japan office located in Tokyo. The Company produces and distributes its own and third party produced antibodies to academic and commercial customers throughout the world with product information and ordering available through the Company’s website, www.abcam.com. Abcam’s vision is to build the largest online catalogue of the best antibodies in the world.

About Transinsight
Transinsight develops knowledge-based semantic solutions in the Life Sciences. Their flagship products www.Go3R.org and www.GoPubMed.com, renowned biomedical search engines, are the first knowledge-based search systems of the next generation for the Life Sciences on the internet. In acknowledgement of the technologies developed by the company, Transinsight has repeatedly been honoured with international awards. The firm works in close collaboration with the Dresden University of Technology. Selected customers are: Unilever, BASF, BfR, StatoilHydro, Wintershall, Abcam and EMBL. For further information on Transinsight on the internet, see www.transinsight.com.

Most Popular Now

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...

New Research Shows Promise and Limitatio…

Published in JAMA Network Open, a collaborative team of researchers from the University of Minnesota Medical School, Stanford University, Beth Israel Deaconess Medical Center and the University of Virginia studied...

G-Cloud 14 Makes it Easier for NHS to Bu…

NHS organisations will be able to save valuable time and resource in the procurement of technologies that can make a significant difference to patient experience, in the latest iteration of...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

Hampshire Emergency Departments Digitise…

Emergency departments in three hospitals across Hampshire Hospitals NHS Foundation Trust have deployed Alcidion's Miya Emergency, digitising paper processes, saving clinical teams time, automating tasks, and providing trust-wide visibility of...

MEDICA HEALTH IT FORUM: Success in Maste…

11 - 14 November 2024, Düsseldorf, Germany. How can innovations help to master the great challenges and demands with which healthcare is confronted across international borders? This central question will be...

A "Chemical ChatGPT" for New M…

Researchers from the University of Bonn have trained an AI process to predict potential active ingredients with special properties. Therefore, they derived a chemical language model - a kind of...

Siemens Healthineers co-leads EU Project…

Siemens Healthineers is joining forces with more than 20 industry and public partners, including seven leading stroke hospitals, to improve stroke management for patients all over Europe. With a total...

MEDICA and COMPAMED 2024: Shining a Ligh…

11 - 14 November 2024, Düsseldorf, Germany. Christian Grosser, Director Health & Medical Technologies, is looking forward to events getting under way: "From next Monday to Thursday, we will once again...

In 10 Seconds, an AI Model Detects Cance…

Researchers have developed an AI powered model that - in 10 seconds - can determine during surgery if any part of a cancerous brain tumor that could be removed remains...